An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

Phase 3 Completed 220 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea

Timeline

Start: 2019-11-25
Primary completion: 2021-03-08
Completion: 2022-01-07

Outcome

Met primary endpoint

registry analysis (superiority test); Arm 1: BMS-986165 vs Arm 2: Placebo; p <0.0001; Odds Ratio (OR) 16.49 (95% CI 6.33 to 42.98); Cochran-Mantel-Haenszel NCT04167462 ↗

registry analysis (superiority test); Arm 1: BMS-986165 vs Arm 2: Placebo; p <0.0001; Odds Ratio (OR) 24.29 (95% CI 9.60 to 61.46); Cochran-Mantel-Haenszel NCT04167462 ↗

Publications

Zhang J, Ding Y, Wang P, Li L, Pan W, Lu Y, Cheng H, Jiang X, Ho JC, Guo S, Seo SJ, Gold LS, Blauvelt A, Zhuo J, Zhong Y, Becker B, Liu L, Banerjee S, Thaci D. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial. J Dermatol. 2025 Sep;52(9):1360-1367. doi: 10.1111/1346-8138.17834. Epub 2025 Jul 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	6 mg	Oral